Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma - Summary - MDSpire

Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma

  • By

  • Jingjing Zhang

  • Xiangdong Gongye

  • Lohitesh Kovooru

  • Emma Andersson

  • Bernice Asiedu

  • Manoj Amrutkar

  • Nadia Gul

  • Caitlyn Myers

  • Sheri Booten

  • Dan Emil Lind

  • Ying Xia

  • Antonio Molinaro

  • Anetta Härtlova

  • Per Lindahl

  • Sue Murray

  • Margit Mahlapuu

  • March 24, 2026

  • 0 min

Share

Objective:

To evaluate the effects of MST3 inhibition on metabolic dysfunction-associated steatohepatitis (MASH) and its potential transition to hepatocellular carcinoma (HCC) in mice, specifically assessing whether MST3 inhibition can prevent HCC development.

Key Findings:
  • MST3 inhibition significantly improved metabolic profiles and reduced MASH severity in mice.
  • No impact on HCC tumor burden was observed despite MST3 inhibition.
  • MST3, MST4, and STK25 expression correlates with MASH severity in human liver biopsies, indicating their potential role as biomarkers.
Interpretation:

While MST3 inhibition effectively alleviates MASH-related metabolic dysfunction, it does not prevent the development of HCC in this model.

Limitations:
  • The study was conducted in a mouse model, which may not fully replicate human disease, particularly in metabolic responses and tumor progression.
  • The long-term effects of MST3 inhibition on HCC development remain unclear and warrant further investigation.
Conclusion:

Targeting MST3 may provide therapeutic benefits for MASH without affecting the risk of HCC, suggesting a potential avenue for treatment in metabolic liver diseases and highlighting the need for further research.

Original Source(s)

Inhibition of MST3, a STE20-type kinase, alleviates metabolic dysfunction-related steatohepatitis in mice without influencing the development of hepatocellular carcinoma

  • by Jingjing Zhang, Xiangdong Gongye, Lohitesh Kovooru, Emma Andersson, Bernice Asiedu, Manoj Amrutkar, Nadia Gul, Caitlyn Myers, Sheri Booten, Dan Emil Lind, Ying Xia, Antonio Molinaro, Anetta Härtlova, Per Lindahl, Sue Murray, Margit Mahlapuu

  • March 24, 2026

Related Content

Associations between prevalent unhealthy lifestyles and the gut microbiota: a comprehensive multi-database bibliometric analysis of pathogenic mechanisms and clinical trajectories

STAT investigates the epidemic killing 178,000 Americans a year

6 takeaways from STAT’s investigation into the U.S. alcohol epidemic